Incyte Targets $3–4 Billion Beyond Jakafi as 2030 Approaches

Incyte told investors its non-Jakafi business should reach $3 billion to $4 billion in sales by 2030, a target that grew more than 30% year over year in the third quarter. The claim rests on approvals that mostly arrive in 2027 or later, and management did not say what happens if they slip.

Chief Executive Officer Bill Meury set out the figures at a Wolfe Research event. His goal: a company that compounds at 10% to 15% annually after 2029, when Jakafi's exclusivity horizon narrows. He framed the outcome plainly — it depends on executing launches and converting clinical programs into approvals, revenue and cash flow. Each of those steps carries its own risk, and Meury did not quantify the downside.

What did Meury say about Jakafi XR and Monjuvi?

Roughly 3% of patients have converted to Jakafi XR, the extended-release formulation. Meury expects the rate to land between 10% and 30%, calling 15% a solid outcome. Incyte expects 80% to 90% formulary coverage by year-end and a clearer read on conversion in early 2027.

The FDA is due to decide on Monjuvi in frontline diffuse large B-cell lymphoma in early 2027. A modest share of that market could double Monjuvi's size, Meury said — though he conceded the competitive landscape has evolved.

Can povorcitinib carry a $1 billion promise?

Incyte expects povorcitinib approval in hidradenitis suppurativa in early 2027 and is negotiating the label with the FDA, hoping it covers patients both before and after biologic therapy. A broad label matters for formulary access. More than 300 Opzelura sales staff would support the launch, targeting about 10,000 physicians.

Data in prurigo nodularis are due near year-end; vitiligo is also in play. Across the three indications, Meury said, povorcitinib could approach or exceed $1 billion in sales — contingent, as always, on approvals and launches.

What is new in the CALR antibody program?

Research chief Pablo Cagnoni said updated data on antibody 989 will appear at the American Society of Hematology meeting, covering more frontline myelofibrosis patients eligible for Jakafi and four additional months of follow-up beyond the abstract. Pivotal studies run in second-line essential thrombocythemia and second-line myelofibrosis; a frontline myelofibrosis trial should start in the first half of 2027, after FDA discussions on an endpoint.

A next-generation antibody, 798, shows greater potency and a longer half-life in preclinical work. Pivotal trials could begin in 2028 — if development proceeds as planned.

Where does the oncology pipeline and dealmaking stand?

The G12D program targets frontline pancreatic cancer with chemotherapy, alongside combinations with a PRMT5 inhibitor and a selective PARP1 inhibitor through partnerships. A pivotal colorectal study launches predominantly in third-line patients; next year Incyte decides between cetuximab and petosemtamab for a frontline combination.

Cagnoni called the TGF-beta bispecific program potentially the pipeline's biggest upside — while cautioning it is not fully de-risked. A phase 3 study in frontline microsatellite-stable colorectal cancer is enrolling ahead of schedule, with progression-free survival data expected next year once the event-driven analysis matures.

On capital, Meury said business development will supplement the pipeline, targeting assets that could win approval and turn accretive between 2029 and 2032. Incyte holds about $4 billion on its balance sheet, a figure that could reach $6 billion if left undeployed.

The plan is coherent on paper; its proof arrives in 2027.